Patents by Inventor Janice Gabrilove

Janice Gabrilove has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
    Publication number: 20060029681
    Abstract: The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
    Type: Application
    Filed: September 30, 2005
    Publication date: February 9, 2006
    Applicant: Memorial Sloan-Kettering Cancer Center
    Inventors: Raymond Warrell, Pier Pandolfi, Janice Gabrilove
  • Human pluripotent hematopoietic colony stimulating factor, method of production and use
    Publication number: 20050063946
    Abstract: Highly purified Pluripotent hematopoietic colony-stimulating factor (pluripotent CSF), a glycoprotein (MW 19,600) constitutively produced by human tumor cells has been highly purified from low serum-containing conditioned medium to apparant homogeneity. Pluripotent CSF supports the growth of human mixed colonies (CFU-GEMM), granulocyte-macrophage colonies (CFU-GM), early erythroid colonies (BFU-E) and induces differentiation of human leukemic cells. The specific activity of the purified pluripotent CSF in the CFU-GM assay is 1.5×108 U/mg protein.
    Type: Application
    Filed: October 5, 2004
    Publication date: March 24, 2005
    Inventors: Karl Welte, Erich Platzer, Janice Gabrilove, Roland Mertelsmann, Malcolm Moore
  • Stimulation, production, culturing and transplantation of stem cells by fibroblast growth factors
    Patent number: 5817773
    Abstract: Fibroblast growth factors are used in vivo, in situ and in vitro to stimulate stem cells, hemopoiesis, the immune system, transplant donor cells, culture and/or engraftment, wherein the use of fibroblast growth factors is disclosed for the stimulation of stem cells or hemopoietic cells, supporting cells and their progeny, in vitro, in situ and in vivo, as well as corresponding engrafting sites in vivo.
    Type: Grant
    Filed: February 23, 1996
    Date of Patent: October 6, 1998
    Assignees: New York University, Sloan-Kettering Institute for Cancer Research
    Inventors: Elaine Lynette Wilson, Janice Gabrilove
  • Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors
    Patent number: 5612211
    Abstract: Fibroblast growth factors are used in vivo, in situ and in vitro to stimulate stem cells, hemopoiesis, the immune system, transplant donor cells, culture and/or engraftment, wherein the use of fibroblast growth factors is disclosed for the stimulation of stem cells or hemopoietic cells, supporting cells and their progeny, in vitro, in situ and in vivo, as well as corresponding engrafting sites in vivo.
    Type: Grant
    Filed: June 15, 1993
    Date of Patent: March 18, 1997
    Assignees: New York University, Sloan-Kettering Institute For Cancer Research
    Inventors: Elaine L. Wilson, Janice Gabrilove